Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
BMJ
    June 2025
  1. KAR P
    Partha Kar: The spending review is an opportunity to reevaluate priorities in diabetes care.
    BMJ. 2025;389:r1175.
    >> Share

  2. LIN J, Huang Y, Xu B, Gu X, et al
    Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial.
    BMJ. 2025;389:e083735.
    >> Share

    April 2025

  3. Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study.
    BMJ. 2025;389:r845.
    >> Share

    February 2025
  4. SHAPIRO SB, Yin H, Yu OHY, Rej S, et al
    Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study.
    BMJ. 2025;388:e080679.
    >> Share

    January 2025
  5. HOPE D, Valabhji J
    SGLT2 inhibitors and dietary calorie restriction for type 2 diabetes remission.
    BMJ. 2025;388:r40.
    >> Share

  6. LIU Y, Chen Y, Ma J, Lin J, et al
    Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.
    BMJ. 2025;388:e081820.
    >> Share

    December 2024
  7. MOTTELSON M, Helby J, Nordestgaard BG, Ellervik C, et al
    Mortality and risk of diabetes, liver disease, and heart disease in individuals with haemochromatosis HFE C282Y homozygosity and normal concentrations of iron, transferrin saturation, or ferritin: prospective cohort study.
    BMJ. 2024;387:e079147.
    >> Share

  8. LIU B, Zong G, Zhu L, Hu Y, et al
    Chocolate intake and risk of type 2 diabetes: prospective cohort studies.
    BMJ. 2024;387:e078386.
    >> Share

    November 2024
  9. IACOBUCCI G
    Diabetes: Global treatment gap is widening, study finds.
    BMJ. 2024;387:q2515.
    >> Share

  10. SCIVIER M
    Quality care is needed for older people with diabetes in care homes-now and for the future.
    BMJ. 2024;387:q2471.
    >> Share

  11. SVANSTROM H, Mkoma GF, Hviid A, Pasternak B, et al
    SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study.
    BMJ. 2024;387:e080925.
    >> Share

    October 2024
  12. MCCORMICK N, Yokose C, Lu N, Wexler DJ, et al
    Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.
    BMJ. 2024;387:e080035.
    >> Share

  13. ALKABBANI W, Suissa K, Gu KD, Cromer SJ, et al
    Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.
    BMJ. 2024;387:e080340.
    >> Share

  14. MENG LC, van Gelder MMHJ, Chuang HM, Chen LK, et al
    Paternal metformin use and risk of congenital malformations in offspring in Norway and Taiwan: population based, cross national cohort study.
    BMJ. 2024;387:e080127.
    >> Share

  15. LIU L, Ke W, Li H, Li F, et al
    Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.
    BMJ. 2024;387:e080122.
    >> Share

  16. AGARWAL A, Zeng X, Li S, Rayner D, et al
    Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.
    BMJ. 2024;387:e080257.
    >> Share

    September 2024
  17. WISE J
    Diabetes: Once weekly insulin could be as effective as daily injections, studies indicate.
    BMJ. 2024;386:q2005.
    >> Share


  18. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study.
    BMJ. 2024;386:q1911.
    >> Share

    August 2024
  19. TU SY, Shao SC, Loh CH, Huang HK, et al
    SGLT-2 inhibitors and dementia.
    BMJ. 2024;386:q1841.
    >> Share

  20. MAHASE E
    Semaglutide's CVD indication could cost US Medicare $145bn extra a year.
    BMJ. 2024;386:q1878.
    >> Share

  21. SHIN A, Koo BK, Lee JY, Kang EH, et al
    Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study.
    BMJ. 2024;386:e079475.
    >> Share

  22. KMIETOWICZ Z
    SGLT-2 inhibitors for diabetes may help prevent dementia, study finds.
    BMJ. 2024;386:q1875.
    >> Share

  23. MAHASE E
    Diabetes: One in 10 patients on NHS's "soups and shakes" diet plan went into remission.
    BMJ. 2024;386:q1733.
    >> Share

    July 2024
  24. MAHASE E
    Semaglutide: FDA publishes warning amid reports of patients overdosing.
    BMJ. 2024;386:q1696.
    >> Share

  25. IACOBUCCI G
    Semaglutide: UK regulator approves drug for prevention of cardiovascular events.
    BMJ. 2024;386:q1660.
    >> Share

  26. MAHASE E
    GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment.
    BMJ. 2024;386:q1645.
    >> Share

  27. LAL N
    India: Doctors report surge in use of off label GLP-1 agonists among rich.
    BMJ. 2024;386:q1605.
    >> Share

  28. DYER C
    People with type 1 diabetes and disordered eating need joined-up care, says coroner after woman's death.
    BMJ. 2024;386:q1597.
    >> Share

  29. VANDERPANT N, Ward E, Farrell E, Theodoraki A, et al
    Insulin for people with type 2 diabetes mellitus.
    BMJ. 2024;386:e078015.
    >> Share

  30. WISE J
    Covid-19: Progression to clinical type 1 diabetes accelerated after infection, study suggests.
    BMJ. 2024;386:q1557.
    >> Share

  31. SETHI J
    Use of language in diabetes: what's in a name?
    BMJ. 2024;386:q1446.
    >> Share

    June 2024
  32. MAHASE E
    GLP-1 shortages will not resolve this year, EMA warns, amid concern over off-label use.
    BMJ. 2024;385:q1448.
    >> Share

  33. FU EL, Wexler DJ, Cromer SJ, Bykov K, et al
    SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    BMJ. 2024;385:e078483.
    >> Share

  34. DOBLE E, Farrow D
    We need to tackle the increasing mountain of wasted plastic and cardboard from diabetes technologies.
    BMJ. 2024;385:q1337.
    >> Share

  35. ZHANG J, Li Y
    Increasing prevalence of type 1 diabetes in older age may be a good sign.
    BMJ. 2024;385:q1322.
    >> Share

  36. YANG K, Yang X, Jin C, Ding S, et al
    Global burden of type 1 diabetes in adults aged 65 years and older, 1990-2019: population based study.
    BMJ. 2024;385:e078432.
    >> Share


  37. New advances in type 1 diabetes.
    BMJ. 2024;385:q1224.
    >> Share

    May 2024
  38. JENKINS AJ, Ogle GD, Scibilia R, Schwarz P, et al
    People who need insulin are particularly vulnerable in disasters and conflicts.
    BMJ. 2024;385:q1109.
    >> Share

  39. BIDULKA P, Lugo-Palacios DG, Carroll O, O'Neill S, et al
    Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
    BMJ. 2024;385:e077097.
    >> Share

    April 2024
  40. MAHASE E
    Diabetes UK defends partnership with Slimming World in face of criticism.
    BMJ. 2024;385:q962.
    >> Share

  41. SIMMS-WILLIAMS N, Treves N, Yin H, Lu S, et al
    Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    BMJ. 2024;385:e078242.
    >> Share

  42. NOLAN T
    The use of continuous glucose monitoring devices in non-diabetic adults ... and other research.
    BMJ. 2024;385:q859.
    >> Share

  43. SETHI J
    Breaking free from the stigma of diabetes.
    BMJ. 2024;385:q890.
    >> Share

  44. BOKINNI Y
    Barbados is in the grip of a diabetic foot amputation crisis.
    BMJ. 2024;385:q350.
    >> Share

  45. PASTERNAK B, Wintzell V, Hviid A, Eliasson B, et al
    Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
    BMJ. 2024;385:e078225.
    >> Share

    March 2024
  46. CHRISTIE B
    Charity calls for Scottish government to increase access to diabetes technology.
    BMJ. 2024;384:q755.
    >> Share

  47. MAHASE E
    Type 1 diabetes: Randox removes adverts after claims that it was using fear to sell genetic test.
    BMJ. 2024;384:q744.
    >> Share

  48. SAUL H, Deeney B, Swaithes L, Hounkpatin H, et al
    Even short periods of diabetes remission are linked to lower risk of heart attack and stroke.
    BMJ. 2024;384:q516.
    >> Share

  49. TANNE JH
    FDA approves first over-the-counter blood glucose monitor for diabetes.
    BMJ. 2024;384:q611.
    >> Share

  50. TANNE JH
    US food manufacturer can say that eating yogurt reduces risk of type 2 diabetes, says FDA.
    BMJ. 2024;384:q569.
    >> Share

    February 2024
  51. LANE MM, Gamage E, Du S, Ashtree DN, et al
    Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses.
    BMJ. 2024;384:e077310.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016